Related references
Note: Only part of the references are listed.Mast Cell-Derived Histamine Regulates Liver Ketogenesis via Oleoylethanolamide Signaling
Alessandra Misto et al.
CELL METABOLISM (2019)
Oleoylethanolamide: The role of a bioactive lipid amide in modulating eating behaviour
J. Sihag et al.
OBESITY REVIEWS (2018)
Oleoylethanolamide increases the expression of PPAR-A and reduces appetite and body weight in obese people: A clinical trial
Payahoo Laleh et al.
APPETITE (2018)
Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice
Jacob D. Brown et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2018)
Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation
Amanda Karolina Soares Silva et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2018)
Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Chun Kit Hung et al.
CLINICS IN LIVER DISEASE (2018)
Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System
Shenglong Zou et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease
Mario Masarone et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2018)
The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis
Feng-Bin Lu et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2018)
Oleoylethanolamide Supplementation Reduces Inflammation and Oxidative Stress in Obese People: A Clinical Trial
Laleh Payahoo et al.
ADVANCED PHARMACEUTICAL BULLETIN (2018)
Therapeutic application of GPR119 ligands in metabolic disorders
Jin Won Yang et al.
DIABETES OBESITY & METABOLISM (2018)
PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD
Barbara Gross et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Treatment of NAFLD with diet, physical activity and exercise
Manuel Romero-Gómez et al.
JOURNAL OF HEPATOLOGY (2017)
The epidemiology of non-alcoholic fatty liver disease
Stefano Bellentani
LIVER INTERNATIONAL (2017)
Oleoylethanolamide: A fat ally in the fight against obesity
Jacob D. Brown et al.
PHYSIOLOGY & BEHAVIOR (2017)
Oleic acid-derived oleoylethanolamide: A nutritional science perspective
Kate J. Bowen et al.
PROGRESS IN LIPID RESEARCH (2017)
The Implication of PGC-1α on Fatty Acid Transport across Plasma and Mitochondrial Membranes in the Insulin Sensitive Tissues
Elzbieta Supruniuk et al.
FRONTIERS IN PHYSIOLOGY (2017)
Non-alcoholic fatty liver disease: An expanded review
Mark Benedict et al.
WORLD JOURNAL OF HEPATOLOGY (2017)
PPARs and nonalcoholic fatty liver disease
Kim H. H. Liss et al.
BIOCHIMIE (2017)
Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis
Schohraya Spahis et al.
ANTIOXIDANTS & REDOX SIGNALING (2017)
Role of bioactive fatty acids in nonalcoholic fatty liver disease
Eva Juarez-Hernandez et al.
NUTRITION JOURNAL (2016)
GPR119: a promising target for nonalcoholic fatty liver disease
Jin Won Yang et al.
FASEB JOURNAL (2016)
Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD
Alexandra Montagner et al.
GUT (2016)
Diet, Weight Loss, and Liver Health in Nonalcoholic Fatty Liver Disease: Pathophysiology, Evidence, and Practice
Giulio Marchesini et al.
HEPATOLOGY (2016)
The satiety factor oleoylethanolamide impacts hepatic lipid and glucose metabolism in goldfish
Miguel Gomez-Boronat et al.
JOURNAL OF COMPARATIVE PHYSIOLOGY B-BIOCHEMICAL SYSTEMIC AND ENVIRONMENTAL PHYSIOLOGY (2016)
Pharmacological management of nonalcoholic fatty liver disease
Diana Barb et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Extracellular Matrix Molecular Remodeling in Human Liver Fibrosis Evolution
Andrea Baiocchini et al.
PLOS ONE (2016)
Pro-Inflammatory Cytokines but Not Endotoxin-Related Parameters Associate with Disease Severity in Patients with NAFLD
Johannie du Plessis et al.
PLoS One (2016)
Oleoylethanolamide exerts anti-inflammatory effects on LPS-induced THP-1 cells by enhancing PPARα signaling and inhibiting the NF-κB and ERK1/2/AP-1/STAT3 pathways
Lichao Yang et al.
SCIENTIFIC REPORTS (2016)
Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients
Gabriela Paredes-Turrubiarte et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2016)
Regulation of Ketone Body Metabolism and the Role of PPARα
Maja Grabacka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Role of APN and TNF-α in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease
X. Lin et al.
GENETICS AND MOLECULAR RESEARCH (2015)
PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis
Sven Francque et al.
JOURNAL OF HEPATOLOGY (2015)
Current efforts and trends in the treatment of NASH
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2015)
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
Michal Pawlak et al.
JOURNAL OF HEPATOLOGY (2015)
Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats
Long Li et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2015)
Gastric bypass in morbid obese patients is associated with reduction in adipose tissue inflammation via N-oleoylethanolamide (OEA)-mediated pathways
Fabrizio Montecucco et al.
THROMBOSIS AND HAEMOSTASIS (2015)
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: An open question
Letitia Adela Maria Streba et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Oleic acid content of a meal promotes oleoylethanolamide response and reduces subsequent energy intake in humans
Ilario Mennella et al.
FOOD & FUNCTION (2015)
Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells
Ling Chen et al.
ONCOTARGET (2015)
Central mechanisms mediating the hypophagic effects of oleoylethanolamide and N-acylphosphatidylethanolamines: different lipid signals?
Adele Romano et al.
FRONTIERS IN PHARMACOLOGY (2015)
Non-alcoholic fatty liver disease in 2015
Monjur Ahmed
WORLD JOURNAL OF HEPATOLOGY (2015)
Vagal afferents are not necessary for the satiety effect of the gut lipid messenger oleoylethanolamide
Elnaz Karimian Azari et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2014)
The PPARα-FGF21 Hormone Axis Contributes to Metabolic Regulation by the Hepatic JNK Signaling Pathway
Santiago Vernia et al.
CELL METABOLISM (2014)
Oleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat
Juan Suarez et al.
DISEASE MODELS & MECHANISMS (2014)
Oleic acid modulates mRNA expression of liver X receptor (LXR) and its target genes ABCA1 and SREBP1c in human neutrophils
Maria Edith Reyes-Quiroz et al.
EUROPEAN JOURNAL OF NUTRITION (2014)
The Transrepressive Activity of Peroxisome Proliferator-Activated Receptor Alpha Is Necessary and Sufficient to Prevent Liver Fibrosis in Mice
Michal Pawlak et al.
HEPATOLOGY (2014)
Role of oleoylethanolamide as a feeding regulator in goldfish
Ana B. Tinoco et al.
JOURNAL OF EXPERIMENTAL BIOLOGY (2014)
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Anders Berg Jorgensen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
Jacy Crosby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
High dietary fat intake influences the activation of specific hindbrain and hypothalamic nuclei by the satiety factor oleoylethanolamide
A. Romano et al.
PHYSIOLOGY & BEHAVIOR (2014)
Dietary Non-Esterified Oleic Acid Decreases the Jejunal Levels of Anorectic N-Acylethanolamines
Thi Ai Diep et al.
PLOS ONE (2014)
Satiety factor oleoylethanolamide recruits the brain histaminergic system to inhibit food intake
Gustavo Provensi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease
Sanja Stojsavljevic et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Oleoylethanolamide: A Novel Potential Pharmacological Alternative to Cannabinoid Antagonists for the Control of Appetite
Adele Romano et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Selective peroxisome proliferator-activated receptora modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
Jean-Charles Fruchart
CARDIOVASCULAR DIABETOLOGY (2013)
Activation of intestinal peroxisome proliferator-activated receptor- increases high-density lipoprotein production
Sophie Colin et al.
EUROPEAN HEART JOURNAL (2013)
Peroxisome Proliferator-activated Receptor α Positively Regulates Complement C3 Expression but Inhibits Tumor Necrosis Factor α-mediated Activation of C3 Gene in Mammalian Hepatic-derived Cells
Denis A. Mogilenko et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance
Mohamed Asrih et al.
JOURNAL OF ENDOCRINOLOGY (2013)
The relationship between oxidative stress and nonalcoholic fatty liver disease: Its effects on the development of nonalcoholic steatohepatitis
Fatma Ucar et al.
REDOX REPORT (2013)
A Gut Lipid Messenger Links Excess Dietary Fat to Dopamine Deficiency
Luis A. Tellez et al.
SCIENCE (2013)
A fatty gut feeling
Daniele Piomelli
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2013)
Fatty Acid Modulation of the Endocannabinoid System and the Effect on Food Intake and Metabolism
Shaan S. Naughton et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2013)
Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease
Michael S. Kostapanos et al.
WORLD JOURNAL OF HEPATOLOGY (2013)
Hepatic Cannabinoid Receptor-1 Mediates Diet-Induced Insulin Resistance via Inhibition of Insulin Signaling and Clearance in Mice
Jie Liu et al.
GASTROENTEROLOGY (2012)
PPAR alpha activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats
Aina Rodriguez-Vilarrupla et al.
JOURNAL OF HEPATOLOGY (2012)
The effect of a dietary supplement (N-oleyl-phosphatidyl-ethanolamine and epigallocatechin gallate) on dietary compliance and body fat loss in adults who are overweight: A double-blind, randomized control trial
Gerald T. Mangine et al.
LIPIDS IN HEALTH AND DISEASE (2012)
The thrifty lipids: endocannabinoids and the neural control of energy conservation
Nicholas V. DiPatrizio et al.
TRENDS IN NEUROSCIENCES (2012)
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
G. Vernon et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Dietary fat decreases intestinal levels of the anorectic lipids through a fat sensor
Thi Ai Diep et al.
FASEB JOURNAL (2011)
Lipid transport function is the main target of oral oleoylethanolamide to reduce adiposity in high-fat-fed mice
Clementine Thabuis et al.
JOURNAL OF LIPID RESEARCH (2011)
Sympathetic Activity Controls Fat-Induced Oleoylethanolamide Signaling in Small Intestine
Jin Fu et al.
JOURNAL OF NEUROSCIENCE (2011)
PPARα Expression Protects Male Mice from High Fat-Induced Nonalcoholic Fatty Liver
Mohamed A. Abdelmegeed et al.
JOURNAL OF NUTRITION (2011)
Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas
Chen Li et al.
PHARMACOLOGY & THERAPEUTICS (2011)
The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases
Sandeep Tyagi et al.
JOURNAL OF ADVANCED PHARMACEUTICAL TECHNOLOGY & RESEARCH (2011)
Nonalcoholic Fatty Liver Disease: Pathology and Pathogenesis
Dina G. Tiniakos et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2010)
Fibrates, Glitazones, and Peroxisome Proliferator-Activated Receptors
Fanny Lalloyer et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery
J. Mark Brown et al.
CURRENT OPINION IN LIPIDOLOGY (2010)
Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications
Elisa Fabbrini et al.
HEPATOLOGY (2010)
Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis
Herbert Tilg et al.
HEPATOLOGY (2010)
The Fat-Induced Satiety Factor Oleoylethanolamide Suppresses Feeding through Central Release of Oxytocin
Silvana Gaetani et al.
JOURNAL OF NEUROSCIENCE (2010)
Analysis of gene expression pattern reveals potential targets of dietary oleoylethanolamide in reducing body fat gain in C3H mice
Clementine Thabuis et al.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2010)
Peroxisome proliferator activated receptor α (PPARα) and PPAR gamma coactivator (PGC-1α) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements
Shulan Song et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2010)
Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo
Gabriel M. Simon et al.
MOLECULAR BIOSYSTEMS (2010)
Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats
Paul M. Johnson et al.
NATURE NEUROSCIENCE (2010)
Plasma anandamide and other N-acylethanolamines are correlated with their corresponding free fatty acid levels under both fasting and non-fasting conditions in women
Michel M. Joosten et al.
NUTRITION & METABOLISM (2010)
CD36 gene deletion decreases oleoylethanolamide levels in small intestine of free-feeding mice
Ana Guijarro et al.
PHARMACOLOGICAL RESEARCH (2010)
Pathogenesis of non-alcoholic fatty liver disease
J. K. Dowman et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2010)
Large-scale trial suggests ethosuximide as best treatment for absence epilepsy
[Anonymous]
FUTURE NEUROLOGY (2010)
Stearoyl-CoA desaturase-1 deficiency attenuates obesity and insulin resistance in leptin-resistant obese mice
Makoto Miyazaki et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Administration of a dietary supplement (N-oleyl-phosphatidylethanolamine and epigallocatechin-3-gallate formula) enhances compliance with diet in healthy overweight subjects: a randomized controlled trial
Mariangela Rondanelli et al.
BRITISH JOURNAL OF NUTRITION (2009)
GPR119 Is Essential for Oleoylethanolamide-Induced Glucagon-Like Peptide-1 Secretion From the Intestinal Enteroendocrine L-Cell
Lina M. Lauffer et al.
DIABETES (2009)
GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis
Hong Lan et al.
JOURNAL OF ENDOCRINOLOGY (2009)
Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats
Jin Fu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2008)
The Lipid Messenger OEA Links Dietary Fat Intake to Satiety
Gary J. Schwartz et al.
CELL METABOLISM (2008)
Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice
Douglas Osei-Hyiaman et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Biological functions and metabolism of oleoylethanolamide
Clementine Thabuis et al.
LIPIDS (2008)
The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats
Antonia Serrano et al.
NEUROPHARMACOLOGY (2008)
Nonalcoholic fatty liver disease and mitochondrial dysfunction
Yongzhong Wei et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α
Sibylle Jaeger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease
N. Mendez-Sanchez et al.
LIVER INTERNATIONAL (2007)
Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine
Jin Fu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Mechanism of oleoylethanolamide on fatty acid uptake in small intestine after food intake and body weight reduction
Yingkui Yang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2007)
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis
Kanji Yamaguchi et al.
HEPATOLOGY (2007)
Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-α
Jesse LoVerme et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders
Benoit Viollet et al.
JOURNAL OF PHYSIOLOGY-LONDON (2006)
Peroxisome proliferator-activated receptor α improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets
Fanny Lalloyer et al.
DIABETES (2006)
Sorting out the roles of PPARα in energy metabolism and vascular horneostasis
P Lefebvre et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis
Sarah Hummasti et al.
MOLECULAR ENDOCRINOLOGY (2006)
Oleylethanolamide impairs glucose tolerance and inhibits insulin-stimulated glucose uptake in rat adipocytes through p38 and JNK MAPK pathways
C González-Yanes et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2005)
Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity
K Proulx et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2005)
Agonists for the peroxisome proliferator-activated receptor-α and the retffionid X receptor inhibit inflammatory responses of microglia
JH Xu et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2005)
Oleoylethanolamide, an endogenous PPAR-α agonist, lowers body weight and hyperlipidemia in obese rats
J Fu et al.
NEUROPHARMACOLOGY (2005)
Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1
XB Wang et al.
JOURNAL OF PHYSIOLOGY-LONDON (2005)
Regulation of food intake by oleoylethanolamide
J Lo Verme et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2005)
The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide
J Lo Verme et al.
MOLECULAR PHARMACOLOGY (2005)
Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice
E Ip et al.
HEPATOLOGY (2004)
A novel function for fatty acid translocase (FAT)/CD36 - Involvement in long chain fatty acid transfer into the mitochondria
SE Campbell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor α (PPAR-α)
M Guzmán et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathway
AE Feldstein et al.
HEPATOLOGY (2004)
PPARα ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats
T Toyama et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Food intake is inhibited by oral oleoylethanolamide
MJ Nielsen et al.
JOURNAL OF LIPID RESEARCH (2004)
Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration
F Oveisi et al.
PHARMACOLOGICAL RESEARCH (2004)
Activation of peroxisome proliferator-activated receptor-α protects the heart from ischemia/reperfusion injury
TL Yue et al.
CIRCULATION (2003)
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α
J Fu et al.
NATURE (2003)
Activation of TRPV1 by the satiety factor oleoylethanolamide
GP Ahern
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Peroxisome proliferator-activated receptor-α agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis
H Kim et al.
DIABETES (2003)
Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice
E Ip et al.
HEPATOLOGY (2003)
Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide
S Gaetani et al.
NEUROPSYCHOPHARMACOLOGY (2003)
Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor α activators
N Vu-Dac et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States
CE Ruhl et al.
GASTROENTEROLOGY (2003)
WY14,643, a peroxisome proliferator-activated receptor α (PPARα) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice
CJ Chou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
An anorexic lipid mediator regulated by feeding
FR de Fonseca et al.
NATURE (2001)
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
G Chinetti et al.
NATURE MEDICINE (2001)
Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity
M Guerre-Millo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
The PPARs: From orphan receptors to drug discovery
TM Willson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
